Moreover, activation of VDR signaling (e.g., with active vitamin D) is in general associated with suppression of tumor growth and potentiation of cancer therapy.[42, 50] Hence, it makes sense to target regulation of TRPM2 expression, a downstream event of VDR, for more specific regulation of osimertinib's therapeutic efficacy. This evidence concerns the gene TRPM2 and neoplasm.